BurstDR shown to be advantageous to traditional neuromod for FBSS, chronic upper & lower limb pain
Abbott released data from a series of studies exploring the efficacy of its BurstDR neuromodulation over traditional neuromod systems for treating chronic pain, touting benefits across a variety of different chronic pain conditions.
Research aimed to explore benefits of BurstDR stimulation over 10 kHz high-frequency stimulation for patients with failed back surgery syndrome, as well as improvements for patients with chronic upper and lower limb pain. Data was collected at centers across Europe, Abbott said, where its BurstDR technology has been approved since 2014.
In a study comparing the efficacy of BurstDR and 10 kHz high-frequency stimulation for treating FBSS, both BurstDR and 10 kHz showed significant decreases in back pain. BurstDR stimulation appeared advantageous over 10kHz stim in reducing the intensity of leg pain over time, according to the study.
Patients with 10kHz therapies also experienced 2 trial failures and 2 treatment failures, while patients who received BurstDR reported 0 trial and 0 treatment failures.
Abbott presented a series of other studies on the BurstDR technology, reinforcing its superiority over traditional neuromodulation technology.
Results from a prospective, multicenter 100-patient clinical follow-up showed that after 1 year, patients treated with BurstDR reported improved quality of life with a significant reduction in catastrophizing pain.
Data from a retrospective analysis of 9 patients showed significant improvements in BurstDR patients with chronic upper limb pain, including significant improvements during activities of daily living, social activities and during resting periods.
In a retrospective analysis of data from 5 patients, researchers found significant improvements in chronic upper and lower limb pain over conventional tonic SCS for patients treated with BurstDR.
“For years, data from single-center, multi-center and randomized controlled clinical trials have confirmed the benefits of BurstDR stimulation for patients suffering from chronic pain. Throughout NANS 2017, the data presented on BurstDR stimulation consistently demonstrated that the therapy is a good option for new groups of patients currently underserved by existing therapy options. It was exciting to receive direct clinical feedback on the impact of this transformational therapy,” Abbott neuromod medical director Dr. Allen Burton said in a prepared statement.
In October, St. Jude said that the FDA granted pre-market approval for its BurstDR spinal cord stimulation technology.